A5012657241- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- SARS-CoV-2 detection and testing
- Long-Term Effects of COVID-19
- Intensive Care Unit Cognitive Disorders
- Respiratory Support and Mechanisms
- Biosensors and Analytical Detection
- Obesity and Health Practices
- Diabetes Treatment and Management
- Venous Thromboembolism Diagnosis and Management
- Neuroendocrine Tumor Research Advances
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Coronary Artery Anomalies
- Sexual function and dysfunction studies
- Heparin-Induced Thrombocytopenia and Thrombosis
- Kawasaki Disease and Coronary Complications
- Menopause: Health Impacts and Treatments
- Urinary Bladder and Prostate Research
- Pneumonia and Respiratory Infections
- Mechanical Circulatory Support Devices
- Global Public Health Policies and Epidemiology
- Frailty in Older Adults
Guy's and St Thomas' NHS Foundation Trust
2020
Our Lady's Hospital
2017
Wythenshawe Hospital
2001
Boston University
2001
Antibody responses to SARS-CoV-2 can be detected in most infected individuals 10-15 d after the onset of COVID-19 symptoms. However, due recent emergence human population, it is not known how long antibody will maintained or whether they provide protection from reinfection. Using sequential serum samples collected up 94 post symptoms (POS) 65 with real-time quantitative PCR-confirmed infection, we show seroconversion (immunoglobulin (Ig)M, IgA, IgG) >95% cases and neutralizing when sampled...
Abstract Antibody (Ab) responses to SARS-CoV-2 can be detected in most infected individuals 10-15 days following the onset of COVID-19 symptoms. However, due recent emergence this virus human population it is not yet known how long these Ab will maintained or whether they provide protection from re-infection. Using sequential serum samples collected up 94 post symptoms (POS) 65 RT-qPCR confirmed SARS-CoV-2-infected individuals, we show seroconversion >95% cases and neutralizing antibody...
There is a clear requirement for an accurate SARS-CoV-2 antibody test, both as complement to existing diagnostic capabilities and determining community seroprevalence. We therefore evaluated the performance of variety testing technologies their potential use tools. Highly specific in-house ELISAs were developed detection anti-spike (S), -receptor binding domain (RBD) -nucleocapsid (N) antibodies used cross-comparison ten commercial serological assays—a chemiluminescence-based platform, two...
Evolution of SARS-CoV-2 in long-term persistent infections is hypothesised to be a major source variants concern (VOC). However, the linkage intra-host into haplotypes that reflect viral subpopulations has been limited by commonly used genomic sequencing techniques. We developed and bioinformatic workflow for identifying full-length spike analysed their diversification over course individuals with inherited or acquired immunodeficiencies. Mutations frequently emerged positions found VOCs...
Abstract There is a clear requirement for an accurate SARS-CoV-2 antibody test, both as complement to existing diagnostic capabilities and determining community seroprevalence. We therefore evaluated the performance of variety testing technologies their potential tools. A highly specific in-house ELISA was developed detection anti-spike (S), -receptor binding domain (RBD) -nucleocapsid (N) antibodies used cross-comparison ten commercial serological assays – chemiluminescence-based platform,...